Dual inhibition of SHP2 and autophagy suppresses NF1-associated malignant peripheral nerve sheath tumors
Ontology highlight
ABSTRACT: Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of premature death for patients with Neurofibromatosis type 1 and no approved targeted therapies are available. Benign plexiform neurofibromas have been successfully treated with selumetinib, a MEK inhibitor, but after progression to MPNST, MEK inhibition alone is not effective. Frequently, adaptive responses to single agent targeted inhibitors invokes alterations in receptor tyrosine kinase expression and feedback regulation that leads to inhibitor bypass. Here, the effects of SHP099, an inhibitor of the protein-tyrosine phosphatase SHP2 (encoded by the PTPN11 gene) was tested alone and in combination with trametinib (MEKi) in an orthotopic implantation murine model of NF1 MPNST with defined gentotype (NI, Nf1-/-;Ink4a/Arf-/-). Kinase enrichment proteomic analysis was performed using tumor tissue from vehicle, SHP099, or trametinib and SHP099 in combination for 5, 15, or 28 days to evaluate the effects on the functional kinome.
INSTRUMENT(S): Q Exactive HF
ORGANISM(S): Mus Musculus (mouse)
SUBMITTER: Steven Angus
LAB HEAD: Luis F. Parada
PROVIDER: PXD035998 | Pride | 2024-11-20
REPOSITORIES: Pride
ACCESS DATA